Intrinsic Value of S&P & Nasdaq Contact Us

MannKind Corporation MNKD NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
58/100
2/7 Pass
SharesGrow Intrinsic Value
$12.62
+360.6%
Analyst Price Target
$9.00
+228.5%

MannKind Corporation (MNKD) — Analyst outlook / Analyst consensus target is. Based on 18 analyst ratings, the consensus is bullish — 8 Buy, 3 Hold, 7 Sell.

The consensus price target is $9.00, representing an upside of 228.5% from the current price $2.74.

Analysts estimate Earnings Per Share (EPS) of $0.11 and revenue of $0.28B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $0.10 vs est $0.11 (missed -5.4%). 2025: actual $0.02 vs est $0.17 (missed -88.3%). Analyst accuracy: 0%.

MNKD Stock — 12-Month Price Forecast

$9.00
▲ +228.47% Upside
Average Price Target
Based on 18 Wall Street analysts offering 12-month price targets for MannKind Corporation, the price target is $9.00.
The average price target represents a +228.47% change from the last price of $2.74.

MNKD Analyst Ratings

Buy
18
Ratings
8 Buy
3 Hold
7 Sell
Based on 18 analysts giving stock ratings to MannKind Corporation in the past 3 months
Rating breakdown
Buy
8 44%
Hold
3 17%
Sell
7 39%
44%
Buy
8 analysts
17%
Hold
3 analysts
39%
Sell
7 analysts

EPS Estimates — MNKD

0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024 Actual $0.10 vs Est $0.11 ▼ 5.7% off
2025 Actual $0.02 vs Est $0.17 ▼ 756.7% off
Profitability Outlook
Company is profitable but with thin earnings per share. EPS trend is declining. Analysts forecast meaningful EPS growth ahead.

Revenue Estimates — MNKD

98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024 Actual $0.286B vs Est $0.281B ▲ 1.6% off
2025 Actual $0.349B vs Est $0.342B ▲ 1.9% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message